Filter Results
:
(509)
Show Results For
-
All HBS Web
(1,290)
- Faculty Publications (509)
Show Results For
-
All HBS Web
(1,290)
- Faculty Publications (509)
←
Page 26 of
509
Results
- January 1975 (Revised May 1983)
- Case
CIBA-GEIGY Corp. (B)
Keywords:
Pharmaceutical Industry
Salter, Malcolm S. "CIBA-GEIGY Corp. (B)." Harvard Business School Case 375-247, January 1975. (Revised May 1983.)
- February 1974
- Case
Listerine Lozenges
Greyser, Stephen A. "Listerine Lozenges." Harvard Business School Case 574-062, February 1974.
- February 1973 (Revised June 1973)
- Case
Listerine Antiseptic (A)
Greyser, Stephen A. "Listerine Antiseptic (A)." Harvard Business School Case 573-060, February 1973. (Revised June 1973.)
- Research Summary
AIDS in Africa: Life, Death and Property Rights
By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought...
View Details
- 2018
- Chapter
Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals
By: Juan Alcacer, John Cantwell and Michelle Gittelman
As the value chain of the pharmaceutical industry disaggregates, upstream discovery is increasingly carried out by small research-specialized firms while downstream development, testing and marketing is conducted by global pharmaceutical firms. Licensing plays an...
View Details
Keywords:
Geographic Location;
Local Range;
Rights;
Research and Development;
Pharmaceutical Industry;
Pharmaceutical Industry
Alcacer, Juan, John Cantwell, and Michelle Gittelman. "Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals." In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. National Bureau of Economic Research, forthcoming.
- Research Summary
Multinational Enterprises and Corporate Responsibility
By: Nien-he Hsieh
Multinational enterprises, especially those operating in developing economies, face wide-ranging demands to help persons whose basic needs are unmet. Pharmaceutical companies, for example, are asked to provide access to life-saving therapies to patients in countries... View Details
- Research Summary
Overview
By: Kyle R. Myers
Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how...
View Details
Keywords:
Technology Networks;
Commercialization;
Science-Based Business;
Research and Development;
Knowledge Management;
Patents;
Innovation Strategy;
Technological Innovation;
Health Care and Treatment;
Entrepreneurship;
Health;
Innovation and Invention;
Science;
Technology;
Knowledge;
Intellectual Property;
Economics;
Microeconomics;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry
- Research Summary
Overview
By: Andy Wu
How can technology entrepreneurs build competitive advantage from the ground up? Professor Andy Wu conducts scholarly research and develops course materials that document how technology entrepreneurs can (1) organize for innovation to create new market opportunities...
View Details
Keywords:
Strategy;
Entrepreneurship;
Venture Capital;
Growth Management;
Organizational Design;
Organizational Structure;
Technology Platform;
Technological Innovation;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
China;
Southeast Asia;
South Asia
- Forthcoming
- Article
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
By: Amitabh Chandra, Jennifer Kao, Kathleen L. Miller and Ariel Dora Stern
Regulators of new products confront a tradeoff between speeding a product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if regulators can use new policy to...
View Details
Keywords:
Innovation and Invention;
Governing Rules, Regulations, and Reforms;
Government Administration;
Research and Development;
Pharmaceutical Industry
Chandra, Amitabh, Jennifer Kao, Kathleen L. Miller, and Ariel Dora Stern. "Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation." Review of Economics and Statistics (forthcoming). (Pre-published online March 18, 2024.)
- ←
- 26